Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?
Files
Publication date
2015
Authors
Mekinian, Arsene
Costedoat-Chalumeau, Nathalie
Masseau, Agathe
Tincani, Angela
De Caroli, Sara
Alijotas-Reig, Jaume
Ruffatti, Amelia
Ambrozic, Ales
Botta, Angela
Le Guern, Véronique
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.
Keywords
Antiphospholipid syndrome, Hydroxychloroquine, Outcome, Taverne, Immunology, Immunology and Allergy, General Medicine, Journal Article, Review
Citation
Mekinian, A, Costedoat-Chalumeau, N, Masseau, A, Tincani, A, De Caroli, S, Alijotas-Reig, J, Ruffatti, A, Ambrozic, A, Botta, A, Le Guern, V, Fritsch-Stork, R, Nicaise-Roland, P, Carbonne, B, Carbillon, L & Fain, O 2015, 'Obstetrical APS : Is there a place for hydroxychloroquine to improve the pregnancy outcome?', Autoimmunity Reviews, vol. 14, no. 1, pp. 23-29. https://doi.org/10.1016/j.autrev.2014.08.040